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-D-ethylglucuronide (EtG) is a stable Phase II metabolite of ethanol which can be detected in
urine samples several days after elimination of ethanol. It is a useful diagnostic parameter for
monitoring abstinence of alcoholics in alcohol withdrawal treatment. For this purpose,
determination in urine is mainly performed by LC-MS, LC-MS/MS, or by GC-MS. For the
mass spectrometric identification and detection of controlled substances in more sensitive
fields such as forensic toxicology, workplace drug testing, doping analysis, and veterinary
organic residue control, official guidelines have been released requiring a chromatographic
separation and a minimum of two mass spectrometric transitions of the analyte. However, for
detection of EtG none of the published LC-MS/MS methods could fulfill the minimum
requirements of any of these guidelines. Therefore, an existing LC-MS/MS method has been
modified by monitoring further MS/MS transitions instead of only one (deprotonated
molecule [M  H]/product ions: m/z 75, 85, 113, and 159 optional) with the aim of
withstanding administrative or court scrutiny in forensic or workplace drug testing cases. Full
method validation has been performed in accordance to guidelines of the German Society of
Toxicology and Forensic Chemistry (GTFCh) and requirements of ISO 17025. One application
field in the United States is a workplace monitoring program to detect surreptitious alcohol use
among recovering health professionals, who by contract had agreed on total abstinence after
drug and alcohol withdrawal therapy. (J Am Soc Mass Spectrom 2004, 15, 188193) © 2004
American Society for Mass Spectrometry
Current biological markers for monitoring recentalcohol consumption remain suboptimal withregard to sensitivity and specificity. Further-
more, these biomarkers can be influenced by age, gen-
der, and a variety of substances and non-alcohol-asso-
ciated diseases, and do not fully cover the time axis for
alcohol intake. Conjugation of ethanol with activated
glucuronic acid in the presence of membrane-bound
mitochondrial UDP glucuronyl transferase represents a
minor detoxification pathway for ethanol: About 0.02–
0.06% (mean) of the dose of ethanol administered is
recovered as -D-ethylglucuronide (EtG) in urine in
humans [1] and—dose dependent—0.5–1.5% in rabbits
[2]. EtG is a non-volatile, water-soluble, stable, direct
metabolite of ethanol that can be detected in various
body fluids, tissues and hair. EtG (C8H14O7) has a
molecular weight of 222 g/mol, and the melting point
(decomposition temperature) is about 150°C. Shortly
after the initial consumption of even small amounts of
ethanol, EtG is formed. It has been detected in urine up
to 80 h after the complete elimination of alcohol from
the body and was not detectable in teetotalers with a 0.1
mg/L cut-off [3, 4]. EtG is unique in covering this
important time span of one to three days after alcohol
uptake. In urine, it can be detected longer than ethanol.
Therefore, EtG meets the need for a sensitive and
specific marker to elucidate alcohol use not detected by
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standard testing [5–13]. Furthermore, EtG has been
detected in hair samples [14–16] and post-mortem
tissues (liver, brain, fat tissue [17]) of alcohol addicts.
Recently, the determination of ethylglucuronide in
urine was shown to be superior to ethanol as a proof of
recent alcohol consumption in a workplace drug testing
program of recovering health professionals [18].
For the detection of EtG in urine and serum, immu-
noassays are under current development [19–21]. How-
ever, to date the development of an immunoassay with
sufficient sensitivity and specificity has been unsuccess-
ful. Therefore, mass spectrometric methods, such as
GC-EI-MS after derivatization, and LC-MS or LC-
MS/MS with negative electrospray ionization, using
selected ion monitoring (of the deprotonated molecule,
m/z 221) and one MS/MS-transition (deprotonated mol-
ecule to fragment ion; m/z 221–75), respectively, have
been applied to the analysis of urine (Table 1). Quanti-
tative analysis has been performed by use of penta
deuterium-labeled internal standard (D5-EtG) or the
glucuronides of ethanol homologues (methylglucu-
ronide, propylglucuronide). Since EtG is a very polar
substance, precipitation or dilution prior to analysis by
GC-MS and LC-MS have been used for sample clean-up
in most published papers. LC-MS or LC-MS/MS meth-
ods are advantageous in comparison with GC-MS
methods because of the reduced need for derivatization
and shorter analysis times (10 min per chromatographic
run) [4, 12]. In our experience, GC-MS with derivatiza-
tion requires much more system maintenance than does
LC-MS, because of the high load of polar matrix which
is present in urine samples. This is important for the
analysis of large numbers of samples.
Guidelines for urine drug testing in the clinical
laboratory have been approved by the National Com-
mittee for Clinical Laboratory Standards (NCCLS) [22].
When the results of urine drug testing can affect an
individual’s reputation, job status, or freedom, forensi-
cally-acceptable analytical procedures must be utilized,
and the findings must be legally defensible. For a
confirmatory analysis in forensic toxicology, guidelines
require chromatographic separation and at least three
ions for compound detection or identification with SIM
when a single quadrupole GC-MS is used [23]. For the
identification of residues by LC-MS/MS analysis, Euro-
pean guidelines require chromatographic separation
and a minimum of two transitions for substance detec-
tion; when LC-MS (single MS) is used, three character-
istic ions are required [24, 25]. None of the published
LC-MS or LC-MS/MS methods for EtG listed in Table 1
fulfilled these requirements, since either only one ion
with optimized “in-source” CID conditions was used
with a single-quadrupole instrument [4, 11], or only one
Table 1. Methods which have been successfully used for the detection of EtG
Method
Derivatization
Specimen
Internal standard
Ionization
m/z-values or transitions
for detection Chromatographic details Ref.
GC-MS Silylation (MSTFA) EI (5%-phenyl)-methylpolysiloxane (DB 5) [13, 31]
Serum/urine m/z 160, 261, 405a
D5-EtG
b (ISTD: 164, 266, 410a)
GC-MS Silylation (MSTFA)b EI (5%-phenyl)-methylpolysiloxane (DB 5) [16]
Hair m/z 261, 292, 375, 405a
Methylglucuronide (ISTD: 391a)
GC-MS Perfluorpropionylation EI 100% dimethylpolysiloxane (DB 1) [32]
Serum m/z 405a, 365, 289, 259
Propylglucuronide (ISTD: 405a, 365, 289, 259)
LC-MS (SIM) No derivatization
Serum
No internal standard
ESI neg.
m/z 221a
(a) Column: TSK-Gel Amide-80, 250mm 
4.6mm, (acrylamide-type); Tosoh, Tokyo,
Japan)
Eluent: 30 mM ammonium acetate-acetonirile
(30:760, v/v)
[11]
(b) Column: Thermoquest Hypercarb
(100mm  2mm), Keystone/Thermo Sci.c
Eluent: 25 mmol formic acid/acetronitrile
(95:5 v/v)
[4]
LC-MS MS No derivatization ESI neg. (a) Column: RP C18b; [12]
Serum, urine, hair 221–75a Eluent: 0.1% formic acid (isocratic)
D5-EtG (ISTD: 226–75) (b) Column: Synergy polar RP; polar-
endcapped phenyl-propyl (Phenomenex)b
[3,14], Eluent: 0.1% formic acid (isocratic) with
post-column addition of acetonitrile
aquantifier ion;
bvalidation was performed using linear regression;
cconfirmation was performed with LC-MSMS with selected samples (one transition: m/z 221–m/z 75)
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characteristic transition was used for EtG by LC-MS/
MS-analysis [12, 14].
Our aim was to develop and to validate an LC-
MS/MS method with at least two transitions for EtG
which would fulfill the requirements for forensic con-
firmatory analysis, thus being suitable for workplace
drug testing programs and forensic toxicological ana-
lysis.
Experimental
EtG and D5-EtG standards were obtained from Medi-
chem (Stuttgart, Germany). HPLC-grade acetonitrile
and formic acid (analytical grade) were purchased from
Merck (Darmstadt, Germany). Deionized water was
prepared with a cartridge-deionizer from Memtech
(Moorenweis, Germany). Sample preparation: To 0.1
mL blank urine or an EtG spiked urine 50 ng D5-EtG (10
L of an aqueous solution, 5 g/mL) was added and
the sample diluted with 0.25 mL methanol. The sample
was centrifuged (14,000 rpms) for ten min at 4°C. Next,
0.25 mL of the clear supernatant were transferred to a
glass autosampler vial (1.5 mL) and evaporated to
dryness by use of a vacuum concentrator (60 min, 45°C,
1 mbar, Alpha RVC, Martin Christ, Osterode, Ger-
many). The dried residue was then redissolved with
0.14 mL of 0.1% formic acid, transferred to a glass micro
insert (0.2 mL volume), and 10 L were injected into the
LC-MS/MS system.
The LC-MS/MS system consisted of an API 365
triple-quadrupole mass-spectrometer fitted with a
turbo ionspray interface (Applied Biosystems/Sciex,
Darmstadt, Germany) and a Shimadzu HPLC system
(two pumps LC10AD Shimadzu, Duisburg, Germany).
Analyses were performed with electrospray ionization
using a turbo ionspray source in negative mode. EtG
was separated at 40°C on a polar-endcapped phenyl-
propyl reversed phase column (Synergy Polar-RP 250
2 mm, 4 m) with a guard column (4 mm 2 mm, same
packing material) (Phenomenex, Aschaffenburg, Ger-
many). The mobile phase consisted of aqueous 0.1%
formic acid (vol/vol) at a flow-rate of 0.2 mL/min. To
enhance signal intensity, acetonitrile was added with a
post-column “tee” before the effluent enters the turbo
ionspray interface. With a six-port/two-way switching
valve (Labpro, Rheodyne, Rohnert Park, CA) the LC-
effluent was admitted to the MS interface only between
4 and 6 mins of the chromatographic retention time. The
turbo ionspray source was operated at 400°C with an
ionization voltage of4 kV, and nitrogen as curtain gas
and nebulizer gas. Optimization of the ion source and
MS/MS parameters for data acquisition were done by
infusion of a 1 g/mL solution of EtG (20 l/min) with
a syringe-pump coupled with a tee-union to the outlet
of the HPLC system using the autotune function of the
Analyst software (Applied Biosystems/Sciex, Darm-
stadt, Germany). Analysis was performed by multi-
reaction monitoring, using the precursor ion at m/z 221
and the fragment ions at m/z 75, 85, 113, and 159 for EtG,
and precursor ion at m/z 226 and fragment ion at m/z 75
for the internal standard D5-EtG (dwell-times: 200 msec
for each transition, defragmentation potential: 16 V,
focusing potential: 140 V, entrance potential: 3 V,
collision energy: 16 eV, collision cell exit potential:
10 V, collision gas pressure: 2.4–0.7  10-5 torr
nitrogen; unit resolution for Q1 and Q3). For method
validation VALISTAT program was used [26].
Results
The most abundant product ions of EtG and D5-EtG
(m/z 75, 85, and 113) (see Figure 1) result from the
Figure 2. Calibration with spiked urine samples.
Figure 1. Product-ion spectra of EtG and D5-EtG (precursor ions
m/z 221 and 226).
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glucuronic acid not including the aglycon ethanol. The
ions with low abundance result from lactonization or
loss of water (m/z 203), additional decarboxylation (m/z
159), loss of ethanol (m/z 113), and water (95) or CO (85).
In positive ionization mode, -D-glucuronides, e.g., of
morphine, codeine and nor-9-carboxy-tetrahydrocan-
nabinol (cannabis metabolite), show a totally different
fragmentation pattern (neutral loss of the glucuronide
at C1, mass difference 176 u and further fragmentation
of the aglycon) [27, 28]. However, in negative mode the
ions at m/z 75, 85, and 113 could also be generated either
by CID or by in-source CID of other glucuronides of
xenobiotics or endogenous substances and could give
rise to mass spectrometric interferences if not separated
by liquid chromatography and by precursor ion filter-
ing using MS/MS.
Validation has been performed using a common
validation procedure [29] with a Microsoft Excel based
validation program (VALISTAT [26]). A linear calibra-
tion model was used for transition 221/75 (base peak)
as quantifier and transition 221/85 (96% base peak
intensity) as qualifier. The less abundant transitions
221/113 ( 46% base peak intensity) and 221/159 (15%
base peak intensity) were not used for method valida-
tion, but can be used as additional qualifiers for analyte
identification. The calibration curve was linear over the
range from 50 to 2000 ng/mL (see Figure 2). Linear
regression [23] with equidistant calibration levels (0, 50,
100, 150, 200, and 250 ng/mL) was used for the calcu-
lation of LOD and LOQ with a significance level of 33%
(k  3): LOD: 52 ng/mL (with -error 10% for the
qualifier) LOQ: 152 ng/mL (-error 1% for quantifier).
Intra-assay repeatability and accuracy (bias) were tested
by replicate analysis of two quality control samples (200
ng/mL and 2000 ng/mL, respectively) in eight assays,
and produced results as follows. Intra-assay repeat-
abilty: for 200 ng/mL, 4.19% relative standard deviation
(RSD) and 0.03% bias; for 2000 ng/mL, 3.78% RSD and
1.94% bias.
Figure 3 shows the typical ion chromatograms of the
quantifier and two additional qualifiers for EtG in a
urine sample (495 ng/mL EtG) obtained from a female
volunteer 8 h after drinking 0.1 L of sparkling wine (9 g
ethanol) in a controlled study. Figure 4 shows the time
course of EtG elimination in this study; due to the
correlation of EtG concentration and creatinine concen-
tration [30], EtG100 was calculated by normalizing the
measured EtG- and creatinine concentrations to a crea-
tinine concentration of 100 mg/dL. In this study with
nine volunteers, no EtG was detected in the baseline
urine samples collected after one week of abstinence,
and no interferences with other compounds were found
in the retention time window of EtG (5.1  0.3 min) for
the transitions of the quantifier and qualifiers.
Conclusions
A validated LC-MS/MS method has been developed
which fulfills the requirements for forensic confirma-
tory analysis for EtG in urine through the use of at least
two MS/MS-transitions for compound identification,
instead of only one transition as published recently by
others. Although this could easily be achieved, none of
the previous LC-MS(MS) methods ever took this possi-
bility into consideration, mainly because the discussion
Figure 3. Ion chromatograms of urine sample of a female volun-
teer 8 h after drinking sparkling wine with 9 g ethanol content (495
ng/mL EtG was determined).
Figure 4. Time course of urine EtG and EtG100 (normalized to
creatinine concentration of 100 mg/dL) of a female volunteer after
drinking sparkling wine (0.1 L) with a total of 9 g ethanol.
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of validity of results produced by LC-MS/MS methods
by selected reaction monitoring has just started in the
workplace and forensic drug testing environments.
Method validation has been performed according to
guidelines of the GTFCh, ISO 17025, and general rules
for bioanalytical method validation [29], which are
rather detailed for testing specificity, regression models,
intra-assay repeatability, and accuracy. In analyzing
more than 1000 urine samples from clinical and forensic
cases, we have found that LC-MS/MS has advantages
over GC-MS analysis [16, 31, 32] because of higher
sample throughput by shorter analysis time (10 min per
run instead of approximately 20 min), no need for
derivatization as in GC-MS, and less contamination of
the chromatographic system.
Until now, no EtG has been detected in baseline
urine samples of volunteers of our study or those
studied by others. These volunteers were social drink-
ers; baseline urine was analyzed after total abstinence
for several days. However even low amounts of ethanol
in the range of 1 to 2 g, which could be ingested with
“alcohol-free” beverages, pharmaceutical preparations
containing ethanol, or by food containing low amounts
of ethanol (e.g., cakes, fruit juices) could give rise to low
urine EtG concentrations. To overcome the potential of
“false positive” results due to the high sensitivity of the
LC-MS/MS method, further studies must include the
definition of cut-off values for EtG determination for
diagnostic purposes. Furthermore, inter-individual dif-
ferences of glucuronidation rates have to be investi-
gated, and the proposal of a cut-off should include
normalization to the creatinine concentration.
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